Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Walgreens settles Medicaid fraud allegations

Executive Summary

Walgreens agrees to pay $35 million to the federal government, 42 states and Puerto Rico to settle claims that it had switched the dosage forms of three drugs prescribed to Medicaid patients in order to receive higher reimbursements. The government alleged Walgreens switched patients from the tablet forms of ranitidine (generic Zantac) and Eldepryl (selegiline) to the more expensive capsule forms and switched those prescribed the capsule form of fluoxetine (generic Prozac) to the tablet form. CVS Caremark settled similar drug-switching claims in March and Omnicare did so in 2006 (1"The Pink Sheet," March 24, 2008, In Brief)

You may also be interested in...



CVS Caremark settles Medicaid charges

CVS Caremark agrees to pay $36.7 million to settle claims by the Justice Department and a number of state attorneys general that it improperly switched patients from the tablet version of ranitidine (generic Zantac) to the more expensive capsules to boost Medicaid reimbursement levels. The payment will go to settle a whistleblower suit filed in 2003 by pharmacist Bernard Lisitza and will be split among the federal government, 23 states and the District of Columbia, and Lisitza, DOJ announces March 18. CVS Caremark also enters into a five-year compliance agreement with HHS to ensure it does not improperly switch drugs in the future. Lisitza initiated a similar but unrelated suit against Omnicare that was settled in November 2006

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel